Your browser doesn't support javascript.
loading
The iHealth-T2D study, prevention of type 2 diabetes amongst South Asians with central obesity and prediabetes: study protocol for a randomised controlled trial.
Kasturiratne, Anuradhani; Khawaja, Khadija I; Ahmad, Sajjad; Siddiqui, Samreen; Shahzad, Khurram; Athauda, Lathika K; Jayawardena, Ranil; Mahmood, Sara; Muilwijk, Mirthe; Batool, Tayyaba; Burney, Saira; Glover, Matthew; Palaniswamy, Saranya; Bamunuarachchi, Vodathi; Panda, Manju; Madawanarachchi, Suren; Rai, Baldeesh; Sattar, Iqra; Silva, Wnurinham; Waghdhare, Swati; Jarvelin, Marjo-Riitta; Rannan-Eliya, Ravindra P; Gage, Heather M; van Valkengoed, Irene G M; Valabhji, Jonathan; Frost, Gary S; Loh, Marie; Wickremasinghe, Ananda R; Kooner, Jaspal S; Katulanda, Prasad; Jha, Sujeet; Chambers, John C.
Afiliación
  • Kasturiratne A; Department of Public Health, Faculty of Medicine, University of Kelaniya, PO Box 06, Thalagolla Road, Ragama, 11010, Sri Lanka.
  • Khawaja KI; Department of Endocrinology & Metabolism, Services Institute of Medical Sciences, Services Hospital, Ghaus ul Azam, Jail Road, Lahore, 54700, Pakistan.
  • Ahmad S; Punjab Institute of Cardiology, Jail Road, Lahore, Pakistan.
  • Siddiqui S; Institute of Endocrinology, Diabetes & Metabolism, Max Super Speciality Hospital, 2, Press Enclave Road, Saket, New Delhi, 110017, India.
  • Shahzad K; Punjab Institute of Cardiology, Jail Road, Lahore, Pakistan.
  • Athauda LK; Department of Public Health, Faculty of Medicine, University of Kelaniya, PO Box 06, Thalagolla Road, Ragama, 11010, Sri Lanka.
  • Jayawardena R; Department of Physiology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.
  • Mahmood S; Department of Endocrinology & Metabolism, Services Institute of Medical Sciences, Services Hospital, Ghaus ul Azam, Jail Road, Lahore, 54700, Pakistan.
  • Muilwijk M; Department of Public and Occupational Health, Amsterdam Public Health research institute, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105, AZ, Amsterdam, The Netherlands.
  • Batool T; Department of Endocrinology & Metabolism, Diabetes Management Centre, Services Hospital, Ghaus-ul-Azam, Jail Road, Lahore, 540000, Pakistan.
  • Burney S; Department of Endocrinology & Metabolism, Diabetes Management Centre, Services Hospital, Ghaus-ul-Azam, Jail Road, Lahore, 540000, Pakistan.
  • Glover M; School of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey, Daphne Jackson Road, Guildford, GU2 7WG, Surrey, England.
  • Palaniswamy S; School of Public Health, Epidemiology and Biostatistics, Imperial College London, St Mary's Campus, Norfolk Place, London, W2 1PG, UK.
  • Bamunuarachchi V; Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland.
  • Panda M; Diabetes Research Unit, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.
  • Madawanarachchi S; Institute of Endocrinology, Diabetes & Metabolism, Max Super Speciality Hospital, 2, Press Enclave Road, Saket, New Delhi, 110017, India.
  • Rai B; Diabetes Research Unit, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.
  • Sattar I; School of Public Health, Epidemiology and Biostatistics, Imperial College London, St Mary's Campus, Norfolk Place, London, W2 1PG, UK.
  • Silva W; Punjab Institute of Cardiology, Jail Road, Lahore, Pakistan.
  • Waghdhare S; School of Public Health, Epidemiology and Biostatistics, Imperial College London, St Mary's Campus, Norfolk Place, London, W2 1PG, UK.
  • Jarvelin MR; Institute of Endocrinology, Diabetes & Metabolism, Max Super Speciality Hospital, 2, Press Enclave Road, Saket, New Delhi, 110017, India.
  • Rannan-Eliya RP; School of Public Health, Epidemiology and Biostatistics, Imperial College London, St Mary's Campus, Norfolk Place, London, W2 1PG, UK.
  • Gage HM; Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland.
  • van Valkengoed IGM; Department of Life Sciences, College of Health and Life Sciences, Brunel University London, Kingston Lane, Uxbridge, Middlesex, UB8 3PH, UK.
  • Valabhji J; Unit of Primary Care, Oulu University Hospital, Oulu, Finland.
  • Frost GS; Institute for Health Policy, 72 Park Street, Colombo, 00200, Sri Lanka.
  • Loh M; Surrey Health Economics Centre, Department of Clinical and Experimental Medicine, University of Surrey, Leggett Building, Daphne Jackson Road, Guildford, GU2 7WG, Surrey, England.
  • Wickremasinghe AR; Department of Public and Occupational Health, Amsterdam Public Health research institute, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105, AZ, Amsterdam, The Netherlands.
  • Kooner JS; Department of Diabetes and Endocrinology, 1st Floor Mint Wing, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, W2 1NY, UK.
  • Katulanda P; 6th Floor Commonwealth Building, Faculty of Medicine, Imperial College London, Hammersmith Campus, Ducane Road, London, W12 ONN, UK.
  • Jha S; School of Public Health, Epidemiology and Biostatistics, Imperial College London, St Mary's Campus, Norfolk Place, London, W2 1PG, UK.
  • Chambers JC; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 308232, Singapore.
Trials ; 22(1): 928, 2021 Dec 18.
Article en En | MEDLINE | ID: mdl-34922608
ABSTRACT

BACKGROUND:

People from South Asia are at increased risk of type 2 diabetes (T2D). There is an urgent need to develop approaches for the prevention of T2D in South Asians that are cost-effective, generalisable and scalable across settings.

HYPOTHESIS:

Compared to usual care, the risk of T2D can be reduced amongst South Asians with central obesity or raised HbA1c, through a 12-month lifestyle modification programme delivered by community health workers.

DESIGN:

Cluster randomised clinical trial (11 allocation to intervention or usual care), carried out in India, Pakistan, Sri Lanka and the UK, with 30 sites per country (120 sites total). Target recruitment 3600 (30 participants per site) with annual follow-up for 3 years. ENTRY CRITERIA South Asian, men or women, age 40-70 years with (i) central obesity (waist circumference ≥ 100 cm in India and Pakistan; ≥90 cm in Sri Lanka) and/or (ii) prediabetes (HbA1c 6.0-6.4% inclusive). EXCLUSION CRITERIA known type 1 or 2 diabetes, normal or underweight (body mass index < 22 kg/m2); pregnant or planning pregnancy; unstable residence or planning to leave the area; and serious illness. ENDPOINTS The primary endpoint is new-onset T2D at 3 years, defined as (i) HbA1c ≥ 6.5% or (ii) physician diagnosis and on treatment for T2D. Secondary endpoints at 1 and 3 years are the following (i) physical

measures:

waist circumference, weight and blood pressure; (ii) lifestyle

measures:

smoking status, alcohol intake, physical activity and dietary intake; (iii) biochemical

measures:

fasting glucose, insulin and lipids (total and HDL cholesterol, triglycerides); and (iv) treatment compliance. INTERVENTION Lifestyle intervention (60 sites) or usual care (60 sites). Lifestyle intervention was delivered by a trained community health worker over 12 months (5 one-one sessions, 4 group sessions, 13 telephone sessions) with the goal of the participants achieving a 7% reduction in body mass index and a 10-cm reduction in waist circumference through (i) improved diet and (ii) increased physical activity. Usual care comprised a single 30-min session of lifestyle modification advice from the community health worker.

RESULTS:

We screened 33,212 people for inclusion into the study. We identified 10,930 people who met study entry criteria, amongst whom 3682 agreed to take part in the intervention. Study participants are 49.2% female and aged 52.8 (SD 8.2) years. Clinical characteristics are well balanced between intervention and usual care sites. More than 90% of follow-up visits are scheduled to be complete in December 2020. Based on the follow-up to end 2019, the observed incidence of T2D in the study population is in line with expectations (6.1% per annum).

CONCLUSION:

The iHealth-T2D study will advance understanding of strategies for the prevention of diabetes amongst South Asians, use approaches for screening and intervention that are adapted for low-resource settings. Our study will thus inform the implementation of strategies for improving the health and well-being of this major global ethnic group. IRB APPROVAL 16/WM/0171 TRIAL REGISTRATION EudraCT 2016-001350-18 . Registered on 14 April 2016. ClinicalTrials.gov NCT02949739 . Registered on 31 October 2016, First posted on 31/10/2016.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Estado Prediabético / Diabetes Mellitus Tipo 2 Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Trials Asunto de la revista: MEDICINA / TERAPEUTICA Año: 2021 Tipo del documento: Article País de afiliación: Sri Lanka

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Estado Prediabético / Diabetes Mellitus Tipo 2 Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Trials Asunto de la revista: MEDICINA / TERAPEUTICA Año: 2021 Tipo del documento: Article País de afiliación: Sri Lanka